Schiedat Fabian, Meuterodt Benjamin, Prull Magnus, Aweimer Assem, Gotzmann Michael, O'Connor Stephen, Perings Christian, Korth Johannes, Lawo Thomas, El-Battrawy Ibrahim, Hanefeld Christoph, Mügge Andreas, Kloppe Axel
Department of Cardiology and Angiology, University Hospital Bergmannsheil Bochum of the Ruhr-University Bochum, Bochum, Germany.
Department of Cardiology and Angiology at Marienhospital Gelsenkirchen, Academic Hospital of the Ruhr University Bochum, Gelsenkirchen, Germany.
Front Cardiovasc Med. 2024 Apr 10;11:1397138. doi: 10.3389/fcvm.2024.1397138. eCollection 2024.
Patients with progressive chronic kidney disease (CKD) are at higher risk of infections and complications from cardiac implantable electronic devices (CIED). In patients with a primary or secondary prophylactic indication, implantable cardiac defibrillators (ICD) can prevent sudden cardiac deaths (SCD). We retrospectively compared transvenous-ICD (TV-ICD) and intermuscularly implanted subcutaneous-ICD (S-ICD) associated infections and complication rates together with hospitalizations in recipients with stage 4 kidney disease.
We retrospectively analyzed 70 patients from six German centers with stage 4 CKD who received either a prophylactic TV-ICD with a single right ventricular lead, 49 patients, or a S-ICD, 21 patients. Follow-Ups (FU) were performed bi-annually.
The TV-ICD patients were significantly older. This group had more patients with a history of atrial arrhythmias and more were prescribed anti-arrhythmic medication compared with the S-ICD group. There were no significant differences for other baseline characteristics. The median and interquartile range of FU durations were 55.2 (57.6-69.3) months. During FU, patients with a TV-ICD system experienced significantly more device associated infections ( = 8, 16.3% vs. = 0; < 0.05), device-associated complications ( = 13, 26.5% vs. = 1, 4.8%; < 0.05) and device associated hospitalizations ( = 10, 20.4% vs. = 1, 4.8%; < 0.05).
In this long-term FU of patients with stage 4 CKD and an indication for a prophylactic ICD, the S-ICD was associated with significantly fewer device associated infections, complications and hospitalizations compared with TV-ICDs.
进展性慢性肾脏病(CKD)患者发生心脏植入式电子设备(CIED)相关感染和并发症的风险更高。对于有一级或二级预防指征的患者,植入式心脏除颤器(ICD)可预防心源性猝死(SCD)。我们回顾性比较了接受经静脉ICD(TV-ICD)和肌间植入皮下ICD(S-ICD)的4期肾病患者的感染率、并发症发生率及住院情况。
我们回顾性分析了来自德国6个中心的70例4期CKD患者,其中49例接受了带有单根右心室导线的预防性TV-ICD,21例接受了S-ICD。每半年进行一次随访(FU)。
TV-ICD组患者年龄显著更大。与S-ICD组相比,该组有更多有心房心律失常病史的患者,且更多患者使用了抗心律失常药物。其他基线特征无显著差异。随访时间的中位数和四分位间距为55.2(57.6 - 69.3)个月。在随访期间,TV-ICD系统的患者发生与设备相关的感染显著更多(= 8,16.3% vs. = 0;< 0.05)、与设备相关的并发症显著更多(= 13,26.5% vs. = 1,4.8%;< 0.05)以及与设备相关的住院显著更多(= 10,20.4% vs. = 1,4.8%;< 0.05)。
在本次对有预防性ICD指征的4期CKD患者的长期随访中,与TV-ICD相比,S-ICD与显著更少的设备相关感染,并发症及住院相关。